The Rising Threat of NDM-CRE: What Healthcare Professionals Need to Know
Carbapenem-resistant Enterobacterales (CRE) are a growing concern in healthcare, and a particularly aggressive strain, New Delhi metallo-beta-lactamase (NDM)-CRE, is rapidly increasing across the United States. These bacteria pose a significant threat due to their resistance to most available antibiotics, leading to higher rates of illness and death. understanding this evolving challenge is crucial for protecting your patients and communities.
What is NDM-CRE and Why is it Dangerous?
NDM-CRE are bacteria that have developed resistance to carbapenems, a class of powerful antibiotics often used as a last resort for severe infections. This resistance is driven by the NDM enzyme, making infections incredibly tough to treat. Consequently, NDM-CRE infections are associated with significant morbidity and mortality.
How Quickly Can NDM-CRE Spread?
Sadly, NDM-CRE has a high potential for rapid spread. Without strict adherence to infection prevention and control protocols, these bacteria can easily move between patients within healthcare facilities and even extend into the broader community.
What’s Driving the Surge in NDM-CRE Cases?
While research is ongoing, several factors are likely contributing to the increase in NDM-CRE:
* Infection Control Gaps: Consistent implementation of core infection control practices is paramount. This includes diligent hand hygiene, appropriate use of gloves and gowns during patient care, and thorough cleaning and disinfection of surfaces.
* Limited & delayed Testing: Manny healthcare settings lack the capacity for rapid NDM-CRE detection. Delayed identification hinders timely treatment, increases transmission rates, and limits opportunities for effective infection control measures.
What Can Healthcare Providers Do? A call to Action from the CDC
The Centers for Disease Control and Prevention (CDC) urges all healthcare professionals to take immediate action. Here’s how you can help combat the spread of NDM-CRE:
- Stay Informed: Remain vigilant about the increasing national threat of NDM-CRE. Familiarize yourself with the specific epidemiology of CRE in your local area.
- Test Promptly: When a CRE infection is suspected, prioritize testing to identify the specific carbapenemase present. This information is vital for selecting the most effective treatment options. Testing is available through clinical and public health laboratories.
- Select Treatment Carefully: Understanding the specific resistance mechanism driving the infection is key. This allows you to appropriately choose antibiotics to manage your patient’s NDM-CRE infection.
- Strengthen Prevention: Reinforce and consistently apply infection prevention and control best practices. This includes:
* Acute Care: Adhering to Contact Precautions, as outlined by the CDC (https://www.cdc.gov/infection-control/hcp/isolation-precautions/summary-recommendations.html).
* Long-Term Care: Implementing Enhanced Barrier Precautions, as detailed by the CDC (https://www.cdc.gov/long-term-care-facilities/hcp/prevent-mdro/ppe.html?CDC_AAref_Val=https://www.cdc.gov/hai/containment/PPE-Nursing-Homes.html).
* Collaboration: Partner with your state/local Healthcare-associated Infections and Antimicrobial Resistance (HAI/AR) Programs to proactively prevent spread.
Further Resources
For a comprehensive understanding of the recent trends in carbapenemase-producing CRE,review the full report: Changes in Carbapenemase-Producing Carbapenem-Resistant Enterobacterales,2019-2023 ([https://www.acpjournals.org/doi/10.7326/ANNALS-25-02404](https://www.acpjournals.org/doi/10.7326/ANNALS-25-
Related reading